1
|
Marcus K, Lelong C, Rabilloud T. What Room for Two-Dimensional Gel-Based Proteomics in a Shotgun Proteomics World? Proteomes 2020; 8:proteomes8030017. [PMID: 32781532 PMCID: PMC7563651 DOI: 10.3390/proteomes8030017] [Citation(s) in RCA: 39] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2020] [Revised: 08/02/2020] [Accepted: 08/04/2020] [Indexed: 02/07/2023] Open
Abstract
Two-dimensional gel electrophoresis was instrumental in the birth of proteomics in the late 1980s. However, it is now often considered as an outdated technique for proteomics—a thing of the past. Although this opinion may be true for some biological questions, e.g., when analysis depth is of critical importance, for many others, two-dimensional gel electrophoresis-based proteomics still has a lot to offer. This is because of its robustness, its ability to separate proteoforms, and its easy interface with many powerful biochemistry techniques (including western blotting). This paper reviews where and why two-dimensional gel electrophoresis-based proteomics can still be profitably used. It emerges that, rather than being a thing of the past, two-dimensional gel electrophoresis-based proteomics is still highly valuable for many studies. Thus, its use cannot be dismissed on simple fashion arguments and, as usual, in science, the tree is to be judged by the fruit.
Collapse
Affiliation(s)
- Katrin Marcus
- Medizinisches Proteom-Center, Medical Faculty & Medical Proteome Analysis, Center for Proteindiagnostics (PRODI) Ruhr-University Bochum Gesundheitscampus, 4 44801 Bochum, Germany;
| | - Cécile Lelong
- CBM UMR CNRS5249, Université Grenoble Alpes, CEA, CNRS, 17 rue des Martyrs, CEDEX 9, 38054 Grenoble, France;
| | - Thierry Rabilloud
- Laboratory of Chemistry and Biology of Metals, UMR 5249, Université Grenoble Alpes, CNRS, 38054 Grenoble, France
- Correspondence: ; Tel.: +33-438-783-212
| |
Collapse
|
2
|
Garibay-Cerdenares OL, Hernández-Ramírez VI, Osorio-Trujillo JC, Gallardo-Rincón D, Talamás-Rohana P. Haptoglobin and CCR2 receptor expression in ovarian cancer cells that were exposed to ascitic fluid: exploring a new role of haptoglobin in the tumoral microenvironment. Cell Adh Migr 2015. [PMID: 26211665 PMCID: PMC4955374 DOI: 10.1080/19336918.2015.1035504] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Haptoglobin (Hp) is an acute-phase protein that is produced by the liver to capture the iron that is present in the blood circulation, thus avoiding its accumulation in the blood. Moreover, Hp has been detected in a wide variety of tissues, in which it performs various functions. In addition, this protein is considered a potential biomarker in many diseases, such as cancer, including ovarian carcinoma; however, its participation in the cancerous processes has not yet been determined. The objective of this work was to demonstrate the expression of Hp and its receptor CCR2 in the ovarian cancer cells and its possible involvement in the process of cell migration through changes in the rearrangement of the actin cytoskeleton using western blot and wound-healing assays and confirming by confocal microscopy. Ovarian cancer cells express both Hp and its receptor CCR2 but only after exposure to ascitic fluid, inducing moderated cell migration. However, when the cells are exposed to exogenous Hp, the expression of CCR2 is induced together with drastic changes in the actin cytoskeleton rearrangement. At the same time, Hp induced cell migration in a much more efficient manner than did ascitic fluid. These effects were blocked when the CCR2 synthetic antagonist RS102895 was used to pretreat the cells. These results suggest that Hp-induced changes in the cell morphology, actin cytoskeleton structure, and migration ability of tumor cells, is possibly “preparing” these cells for the potential induction of the metastatic phenotype.
Collapse
Affiliation(s)
- O L Garibay-Cerdenares
- a Departamento de Infectómica y Patogénesis Molecular , CINVESTAV, IPN.,c Present address: Unidad Académica de Ciencias Químico Biológicas; Universidad Autónoma de Guerrero (Cátedra CONACYT)
| | | | | | - D Gallardo-Rincón
- b Departamento de Oncología Médica ; Instituto Nacional de Cancerología , México, D.F
| | - P Talamás-Rohana
- a Departamento de Infectómica y Patogénesis Molecular , CINVESTAV, IPN
| |
Collapse
|
3
|
Garibay-Cerdenares OL, Hernández-Ramírez VI, Osorio-Trujillo JC, Hernández-Ortíz M, Gallardo-Rincón D, Cantú de León D, Encarnación-Guevara S, Villegas-Pineda JC, Talamás-Rohana P. Proteomic identification of fucosylated haptoglobin alpha isoforms in ascitic fluids and its localization in ovarian carcinoma tissues from Mexican patients. J Ovarian Res 2014; 7:27. [PMID: 24576319 PMCID: PMC3943579 DOI: 10.1186/1757-2215-7-27] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2013] [Accepted: 02/19/2014] [Indexed: 12/18/2022] Open
Abstract
Background Ovarian cancer is the most lethal gynecologic disease due to delayed diagnosis, and ascites production is a characteristic of patients in advanced stages. The aim of this study was to perform the proteomic analysis of ascitic fluids of Mexican patients with ovarian carcinoma, in order to detect proteins with a differential expression pattern in the continuing search to identify biomarkers for this disease. Methods Samples were collected from 50 patients from the Instituto Nacional de Cancerología of México under informed consent and with approval of the bioethics and scientific committees. After elimination of abundant proteins (Albumin/IgGs) samples were processed for 2D electrophoresis and further protein identification by Mass Spectrometry (MALDI-TOF). Molecules of interest were followed by western blot and lectin binding assays, and their tissue location by histo-immunofluorescence and confocal analysis. Results and discussion An area with a differential expression pattern among samples was located in the 2D gels. Identified proteins were 6 alpha 1 isoforms and 1 alpha 2 isoform of Haptoglobin, and 2 isoforms of Transthyretin. While Transthyretin isoforms were constitutively expressed in all samples, clear differences in the expression pattern of Haptoglobin alpha isoforms were found. Moreover, increased levels of fucosylation of Haptoglobin alpha isoforms analyzed in 40 samples by Aleuria aurantia lectin binding by 1D overlay assay showed a positive correlation with advanced stages of the disease. Tissue detection of Haptoglobin and its fucosylated form, by histo-immunofluorescence in biopsies of ovarian cancer, also showed a correlation with ovarian cancer progression. Moreover, results show that fucosylated Haptoglobin is produced by tumor cells. Conclusions Increased numbers of highly fucosylated Haptoglobin alpha isoforms in ascitic fluids and the presence of fucosylated Haptoglobin in tumor tissues of ovarian cancer Mexican patients associated with advanced stages of the disease, reinforce the potential of fucosylated Haptoglobin alpha isoforms to be characterized as biomarkers for disease progression.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Patricia Talamás-Rohana
- Departamento de Infectómica y Patogénesis Molecular, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Av, Instituto Politécnico Nacional 2508, Col, San Pedro Zacatenco, Delegación Gustavo A, Madero, México, D,F, 07360, México.
| |
Collapse
|
4
|
Marchi N, Mazzone P, Fazio V, Mekhail T, Masaryk T, Janigro D. ProApolipoprotein A1: a serum marker of brain metastases in lung cancer patients. Cancer 2008; 112:1313-24. [PMID: 18257091 DOI: 10.1002/cncr.23314] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
BACKGROUND Central nervous system (CNS) diagnostics is a promising tool for detection of neurological disorders, including brain metastases. One of the earliest applications of CNS diagnostics was based on serum markers of blood-brain barrier (BBB) dysfunction, which often correlates with acute, chronic, or incipient brain disease. In the case of brain metastases, serum levels of S100beta demonstrated a good negative predictive value comparable to radiologic investigations. However, a confounding factor was the presence of BBB changes due to cerebrovascular disease. METHODS Of 103 patients enrolled in a lung cancer study, greater than 50% presented with magnetic resonance imaging (MRI) changes consistent with chronic cerebrovascular disease and reflected by elevated serum S100beta. To unveil serum protein, the authors used proteomic techniques that allow discrimination between patients with brain metastases and lung cancer patients affected by cerebrovascular ischemic changes without infiltrating tumor. RESULTS ProApolipoprotein A1, transferrin, haptoglobin, and transthyretin were upregulated in patients affected by chronic cerebrovascular disease and brain metastases compared with those affected only by vascular diseases. ProApolipoprotein A1 was significantly increased (p<.05) in patients with CNS disease. CONCLUSIONS In conclusion, these data support the use of serum markers for the early detection of brain metastases. ProApolipoprotein A1 may be used in conjunction with S100beta for serum-based, MRI-independent diagnosis of metastatic brain tumors.
Collapse
Affiliation(s)
- Nicola Marchi
- Cerebrovascular Research, Department of Neurosurgery, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio 44195, USA
| | | | | | | | | | | |
Collapse
|
5
|
Bermúdez-Crespo J, López JL. A better understanding of molecular mechanisms underlying human disease. Proteomics Clin Appl 2007; 1:983-1003. [PMID: 21136752 DOI: 10.1002/prca.200700086] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2007] [Indexed: 01/06/2023]
Abstract
This review summarises and discusses the degree to which proteomics is contributing to medical care, providing examples and signspots for future directions. Why do genomic approaches provide a limited view of gene expression? Because of the multifactorial nature of many diseases, proteomics enables us to understand the molecular basis of disease, not only at the organism, whole-cell or tissue levels, but also in subcellular structures, protein complexes and biological fluids. The application of proteomics in medicine is expected to have a major impact by providing an integrated view of individual disease processes. This review describes several proteomic platforms and examines the role of proteomics as a tool for clinical biomarker discovery, the identification of prognostic and earlier diagnostic markers, their use in monitoring the effects of drug treatments and eventually find more efficient and safer therapeutics for a wide range of pathologies.
Collapse
Affiliation(s)
- José Bermúdez-Crespo
- Department of Genetics, Faculty of Biology, University of Santiago de Compostela, Santiago de Compostela, Spain
| | | |
Collapse
|
6
|
Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 2004; 96:353-6. [PMID: 14996856 DOI: 10.1093/jnci/djh056] [Citation(s) in RCA: 337] [Impact Index Per Article: 16.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Affiliation(s)
- Eleftherios P Diamandis
- Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada.
| |
Collapse
|
7
|
Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 2004; 3:367-78. [PMID: 14990683 DOI: 10.1074/mcp.r400007-mcp200] [Citation(s) in RCA: 516] [Impact Index Per Article: 25.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Serum proteomic profiling, by using surfaced-enhanced laser desorption/ionization-time-of-flight mass spectrometry, is one of the most promising new approaches for cancer diagnostics. Exceptional sensitivities and specificities have been reported for some cancer types such as prostate, ovarian, breast, and bladder cancers. These sensitivities/specificities are far superior to those obtained by using classical cancer biomarkers. In this review, I concentrate more on questions that cast doubt on the results reported and propose experiments to investigate these questions in detail, before the technique is used at the clinic. It is clear that the method needs to be externally and thoroughly validated before clinical implementation is warranted.
Collapse
Affiliation(s)
- Eleftherios P Diamandis
- Department of Pathology and Laboratory Medicine, Mount Sinai Hospital,and Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada.
| |
Collapse
|
8
|
Abstract
For about half a century, the binding of drugs to plasma albumin, the "silent receptor," has been recognized as one of the major determinants of drug action, distribution, and disposition. In the last decade, the binding of drugs, especially but not exclusively basic entities, to another plasma protein, alpha 1-acid glycoprotein (AAG), has increasingly become important in this regard. The present review points out that hundreds of drugs with diverse structures bind to this glycoprotein. Although plasma concentration of AAG is much lower than that of albumin, AAG can become the major drug binding macromolecule in plasma with significant clinical implications. Also, briefly reviewed are the physiological, pathological, and genetic factors that influence binding, the role of AAG in drug-drug interactions, especially the displacement of drugs and endogenous substances from AAG binding sites, and pharmacokinetic and clinical consequences of such interactions. It can be predicted that in the future, rapid automatic methods to measure binding to albumin and/or AAG will routinely be used in drug development and in clinical practice to predict and/or guide therapy.
Collapse
Affiliation(s)
- Z H Israili
- Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
| | | |
Collapse
|
9
|
|
10
|
Neale EJ, Wong WS, Arumanayagam M, Chang MZ. The clinical significance of the serum haptoglobin concentration in patients with invasive cervical carcinoma. Aust N Z J Obstet Gynaecol 1989; 29:197-9. [PMID: 2604646 DOI: 10.1111/j.1479-828x.1989.tb01718.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The serum haptoglobin concentration was measured by rate nephalometry in 56 patients with invasive carcinoma of the cervix, and in 24 women with no evidence of cervical pathology who served as control subjects. There was a significant difference in the mean serum haptoglobin concentration (p less than 0.005) between the 2 groups of patients. However there was no significant correlation between the serum haptoglobin concentration and the clinical stage of the disease. From our data we propose that a serum haptoglobin concentration greater than 96 mg/dl is suggestive of invasive carcinoma of the cervix, and that this may be used as additional investigation in the initial assessment of such patients.
Collapse
Affiliation(s)
- E J Neale
- Department of Obstetrics and Gynaecology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin
| | | | | | | |
Collapse
|
11
|
Piver MS, Moyer M, Diakun K, Lele SB, Chu TM. Serum alpha 1-acid glycoprotein in epithelial ovarian cancer. Gynecol Oncol 1988; 29:305-8. [PMID: 3345951 DOI: 10.1016/0090-8258(88)90229-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Fifty-six patients with ovarian adenocarcinoma receiving chemotherapy were monitored with serum alpha 1-acid glycoprotein (AGP) levels. The mean and standard deviation of serum AGP levels for 63 healthy controls were 0.88 +/- 0.469 mg/ml. A serum level above 1.80 mg/ml was considered as above normal level. Five patients had evidence of persistent ovarian carcinoma and had elevated AGP levels. Sixteen patients had normal serum AGP levels and had no evidence of persistent ovarian cancer at second-look laparotomy. However, 35 patients had false-negative AGP levels at the time they had persistent tumor. Although the specificity of the AGP level was 100%, the sensitivity was only 12.5% and the overall accuracy 37%. Therefore, it would appear that serum AGP levels are not of value in monitoring patients with ovarian adenocarcinoma.
Collapse
Affiliation(s)
- M S Piver
- Department of Gynecologic Oncology, Roswell Park Memorial Institute, Buffalo, New York
| | | | | | | | | |
Collapse
|
12
|
Fish RG, Shelley MD, Maughan T, Rocker I, Adams M. The clinical value of serum CA125 levels in ovarian cancer patients receiving platinum therapy. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY 1987; 23:831-5. [PMID: 3308479 DOI: 10.1016/0277-5379(87)90287-2] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Serum CA125 concentrations are elevated in 60% (49/86) of patients, with histologically proven residual adenocarcinoma of the ovary, before chemotherapy. The frequency of elevated levels correlates with stage of disease and tumour size but not histological tumour type. Serial antigen determinations in 44 patients receiving monthly i.v. infusions of platinum therapy suggest that an elevated serum CA125 concentration after chemotherapy may identify the presence of residual tumour but a serum antigen level falling into the normal range does not always indicate the complete eradication of tumour. The role of this serum marker is limited by lack of sensitivity for small tumour masses.
Collapse
Affiliation(s)
- R G Fish
- South Wales Radiotherapy and Oncology Service, Velindre Hospital, Whitchurch, Cardiff, U.K
| | | | | | | | | |
Collapse
|
13
|
Chan S, Gabra H, Hill F, Evan G, Sikora K. A novel tumour marker related to the c-myc oncogene product. Mol Cell Probes 1987; 1:73-82. [PMID: 3331171 DOI: 10.1016/0890-8508(87)90008-9] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
We have studied the utility of the c-myc oncogene product as tumour marker using a set of monoclonal antibodies raised against synthetic peptides constructed from sequence data of the human c-myc oncoprotein. One antibody, Myc1-9E10, raised against the C-terminal 32 amino acids, has been shown to detect specifically the 62 kDa c-myc gene product in tumour cells. Immunoblotting of sera and urine with this antibody consistently revealed a single 40 kDa band (p40). Quantitative analysis using dilution dot immunoblotting demonstrated a considerable increase in the titre of p40 in the sera of 51 patients with a wide range of advanced solid tumours when compared with 17 healthy controls and 50 patients with non-malignant diseases. Serial measurement of the p40 titre in 12 patients with resected colorectal carcinoma shows a gradual return to normal with a half-life of 7 days. Our data suggests that p40 may be a useful new marker for monitoring tumour activity.
Collapse
Affiliation(s)
- S Chan
- Department of Clinical Oncology, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK
| | | | | | | | | |
Collapse
|
14
|
Shelley MD, Fish RG. Evaluation of an immunoradiometric assay for the detection of an ovarian tumour marker, CA125, in serum. Ann Clin Biochem 1986; 23 ( Pt 3):292-6. [PMID: 3466568 DOI: 10.1177/000456328602300308] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
An immunoradiometric assay, that uses a monoclonal antibody attached to a solid support and developed for the detection of the ovarian tumour antigen, CA125, in serum, has been evaluated. The method was simple to perform, with reagents having a shelf-life of approximately 4 weeks. The potentials and limitations of this test are discussed.
Collapse
|